rss0343 tablets
Non-cystic Fibrosis Bronchiectasis
Reistone Biopharma Company LimitedPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
21 Active assets in the Non-cystic Fibrosis Bronchiectasis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ciprofloxacin Centre Hospitalier Intercommunal Creteil | Phase 4 | BBB |
Azithromycin Assiut University | Phase 4 | BBB |
Lipitor University of Edinburgh | Phase 4 | BB |
Theophylline The First Affiliated Hospital of Guangzhou Medical University | Phase 4 | BB |
Roflumilast The University of Hong Kong | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →